Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Given Consensus Rating of “Moderate Buy” by Analysts

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) has been assigned an average recommendation of “Moderate Buy” from the six brokerages that are presently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, four have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $39.00.

ARTV has been the subject of a number of research analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Artiva Biotherapeutics in a research report on Tuesday, July 21st. HC Wainwright raised their price objective on Artiva Biotherapeutics from $15.00 to $35.00 and gave the company a “buy” rating in a research report on Friday, May 8th. Needham & Company LLC restated a “buy” rating and set a $41.00 price objective on shares of Artiva Biotherapeutics in a research note on Monday, June 8th. Wall Street Zen raised Artiva Biotherapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 8th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Artiva Biotherapeutics in a research note on Tuesday, May 26th.

Insider Transactions at Artiva Biotherapeutics

In other news, Director Ra Capital Management, L.P. acquired 24,944 shares of the stock in a transaction on Friday, July 31st. The stock was bought at an average price of $9.93 per share, with a total value of $247,693.92. Following the completion of the transaction, the director directly owned 17,329,570 shares of the company’s stock, valued at $172,082,630.10. The trade was a 0.14% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Insiders have purchased a total of 1,965,251 shares of company stock valued at $16,188,035 over the last three months. 1.80% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Marshall Wace LLP acquired a new stake in Artiva Biotherapeutics during the 2nd quarter valued at $79,000. Qube Research & Technologies Ltd purchased a new position in Artiva Biotherapeutics in the 2nd quarter valued at about $58,000. Jane Street Group LLC purchased a new position in Artiva Biotherapeutics in the 2nd quarter valued at about $67,000. Bridgeway Capital Management LLC acquired a new stake in shares of Artiva Biotherapeutics during the second quarter valued at about $53,000. Finally, BNP Paribas Financial Markets grew its stake in shares of Artiva Biotherapeutics by 14,463.5% during the third quarter. BNP Paribas Financial Markets now owns 118,547 shares of the company’s stock valued at $340,000 after acquiring an additional 117,733 shares in the last quarter.

Artiva Biotherapeutics Stock Performance

Artiva Biotherapeutics stock traded down $0.01 during midday trading on Monday, reaching $10.91. The stock had a trading volume of 43,696 shares, compared to its average volume of 381,558. The stock’s 50-day simple moving average is $10.17 and its 200 day simple moving average is $8.25. Artiva Biotherapeutics has a twelve month low of $2.22 and a twelve month high of $14.53. The stock has a market capitalization of $533.63 million, a PE ratio of -3.32 and a beta of 2.16.

Artiva Biotherapeutics (NASDAQ:ARTV) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.63) EPS for the quarter, hitting the consensus estimate of ($0.63). Equities analysts predict that Artiva Biotherapeutics will post -2.62 earnings per share for the current fiscal year.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.